Universal Ibogaine (TSXV:IBO) Debt-to-Equity : 1.59 (As of Jan. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Universal Ibogaine Debt-to-Equity?

Universal Ibogaine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.13 Mil. Universal Ibogaine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$2.67 Mil. Universal Ibogaine's Total Stockholders Equity for the quarter that ended in Jan. 2024 was C$1.76 Mil. Universal Ibogaine's debt to equity for the quarter that ended in Jan. 2024 was 1.59.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Universal Ibogaine's Debt-to-Equity or its related term are showing as below:

TSXV:IBO' s Debt-to-Equity Range Over the Past 10 Years
Min: -15 Med: 0.72 Max: 1.71
Current: 1.59

During the past 7 years, the highest Debt-to-Equity Ratio of Universal Ibogaine was 1.71. The lowest was -15.00. And the median was 0.72.

TSXV:IBO's Debt-to-Equity is ranked worse than
93.54% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs TSXV:IBO: 1.59

Universal Ibogaine Debt-to-Equity Historical Data

The historical data trend for Universal Ibogaine's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Universal Ibogaine Debt-to-Equity Chart

Universal Ibogaine Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Jul22

Jul23

Debt-to-Equity

Get a 7-Day Free Trial

-15.00

0.44

1.59

Universal Ibogaine Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Equity	Get a 7-Day Free Trial															0.87	1.21	1.59	1.71	1.59

Competitive Comparison of Universal Ibogaine's Debt-to-Equity

For the Biotechnology subindustry, Universal Ibogaine's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Universal Ibogaine's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Universal Ibogaine's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Universal Ibogaine's Debt-to-Equity falls into.

Universal Ibogaine Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Universal Ibogaine's Debt to Equity Ratio for the fiscal year that ended in Jul. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(1.815	+	0.962)	/	1.752
	=	1.59

Universal Ibogaine's Debt to Equity Ratio for the quarter that ended in Jan. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.131	+	2.666)	/	1.755
	=	1.59

Universal Ibogaine (TSXV:IBO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Universal Ibogaine Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Universal Ibogaine's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Universal Ibogaine (TSXV:IBO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Universal Ibogaine Inc (TSXV:IBO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

IBOGF:USA JC4:Germany

Address

400 3rd Avenue South west, Suite 1470, Calgary, AB, CAN, T2P 4H2

Website

https://www.universalibogaine.com

Universal Ibogaine Inc develops a platform of addiction treatment clinics, which use ibogaine as a primary modality for the interruption and ideally cessation of addictions to primarily opioids such as oxycodone, heroin, fentanyl, as well as alcohol, cocaine, and other stimulants. It runs addiction clinics it has a research partner clinic in Mexico.

Universal Ibogaine (TSXV:IBO) Headlines

No Headlines